Medicaid covers GLP-1 weight-loss drugs in just 13 states
Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.
Map Shows States Where Weight Loss Drugs are Most Popular
Kentucky, Alaska and Alabama are the three states where weight loss drugs are most used, and Hawaii, Arizona and Colorado sit at the other end of the spectrum, a report has revealed. Glucagon-like peptide-1 (GLP-1) receptor analogs are drugs that mimic fullness hormone GLP-1 and have been shown to reduce appetite,
The Impact of New Weight Loss Drugs on Dietetics
The Impact of New Weight Loss Drugs on Dietetics By Carrie Dennett, MPH, RDN Today’s Dietitian Vol. 26 No. 9 P. 14 What’s changed for weight-inclusive and weight management dietitians?
Medicaid Covers GLP-1 Meds for Obesity in Just 13 States
Expanding Medicaid coverage of these drugs could increase access for the almost 40% of adults and 26% of children with obesity in Medicaid,” wrote the research team led by se
Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs
These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates appetite and digestion. The medications control blood sugar and help people eat less,
States slow to cover GLP-1s for weight loss
Axios Visuals Budget pressures have kept all but 13 states from covering GLP-1 drugs for weight loss through their Medicaid programs, a new report from KFF shows. Why it matters: The restrictive policies add to equity concerns around the blockbuster drugs,
Glucagon-like peptide-1 receptor agonists tied to lower risk for early-onset colorectal cancer
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer ...
Medscape1d
FDA Updates GLP-1 Label with Pulmonary Aspiration Warning
On November 5, the US Food and Drug Administration (FDA) updated the labels for all glucagon-like peptide 1 receptor agonists (GLP-1 RA) with a warning about pulmonary aspiration during general ...
Renal & Urology News20h
Novel Diabetes Drugs Promise a New Era in Kidney Care
SGLT2 inhibitors and GLP-1 receptor agonists exhibit renoprotective effects in patients with CKD with and without diabetes.
2minutemedicine.com9d
Glucagon-like peptide-1 receptor agonists may impact outcomes of endoscopy
The use of glucagon-like peptide 1 (GLP-1) receptor agonists in adults with type 2 diabetes mellitus (T2DM) was not ...
Guidance issued for safe use of GLP-1 RAs in the perioperative period
In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, ...
Today's Dietitian magazine14h
Do Certain Diabetes Drugs Increase the Risk of Acute Kidney Injury in Patients Taking Anti-Cancer Therapies?
News Do Certain Diabetes Drugs Increase the Risk of Acute Kidney Injury in Patients Taking Anti-Cancer Therapies? Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medicatio ...
2minutemedicine.com7d
Glucagon-like peptide 1 receptor agonists may decrease rates of inflammatory bowel disease flares
The use of glucagon-like peptide 1 (GLP-1) agonists in patients with inflammatory bowel disease (IBD) was associated with few ...
Neurology Advisor2d
Risk for Suicidal Ideation, Attempts Down With GLP1-RA Treatment in Teens With Obesity
For adolescents with obesity, GLP1-RA treatment is associated with a reduced risk for suicidal ideation or attempts.
The Motley Fool12d
This Is Huge News for Novo Nordisk (Hint: It Doesn't Involve Ozempic)
Rybelsus is an oral glucagon-like peptide-1 (GLP-1) agonist and sibling medication to Ozempic and Wegovy. Per a phase 3 trial, Rybelsus was found to reduce cardiovascular risk among patients with ...
Verywell Health on MSN13h
Does Ozempic Impact Kidney Health?
Ozempic (semaglutide) may impact kidney health in certain people, especially those with diabetes. Learn more about what the ...